---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-055193"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T10:58:01.508032+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics appoints Deloitte & Touche as new independent auditor

## Summary
- Deloitte & Touche LLP appointed as independent registered public accounting firm effective October 19, 2023.
- No disagreements, reportable events, or prior consultations with Deloitte regarding accounting principles.
- Appointment follows completion of merger with Dianthus Therapeutics OpCo, Inc. in September 2023.

## SEC filing metadata
- accession: 0000950170-23-055193
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017023055193/0000950170-23-055193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017023055193/dnth-20231019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-055193
- JSON: https://secwatch.observer/filing/0000950170-23-055193.json
- Plain text: https://secwatch.observer/filing/0000950170-23-055193.txt

## Key facts
- Auditor Changes
  Dianthus Therapeutics, Inc. /DE/ engaged Deloitte & Touche LLP as its auditor.
  - Action: engagement
  - Auditor: Deloitte & Touche LLP
  source text: on September 11, 2023, following the completion of the merger between the subsidiary of Dianthus Therapeutics, Inc. (the "Company," formerly known as Magenta Therapeutics, Inc.) and Dianthus Therapeutics OpCo, Inc. (formerly known as Dianthus Therapeutics, Inc.), the Audit Committee of the Company approved the appointment of Deloitte & Touche LLP (“Deloitte”) as the independent registered public accounting firm of the Company. The Company’s engagement of Deloitte was subject to completion of Deloitte’s standard client acceptance procedures and execution of an engagement letter, which was fully executed by the Company on October 19, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017023055193/0000950170-23-055193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.